Samchundang Pharmaceutical Surpasses 1 Million KRW Intraday on the 24th
Soars 300% Since the Beginning of the Year, Becomes KOSDAQ's Leading Stock
Rising Expectations for Oral Obesity Treatments and Oral Insulin

Sancheondang Pharmaceutical Headquarters, Seocho-gu, Seoul. Sancheondang Pharmaceutical

Sancheondang Pharmaceutical Headquarters, Seocho-gu, Seoul. Sancheondang Pharmaceutical

View original image

Samchundang Pharmaceutical, the leading stock on KOSDAQ, has continued its solo rally despite external uncertainties, finally achieving the status of a "king stock" (a share price of 1 million KRW). The stock has surged more than 300% just this year, a rise largely attributed to strong market expectations for the world's first oral insulin.


Samchundang Pharmaceutical Achieves ‘King Stock’ Status During Trading... Six Consecutive Days of Gains

According to the Korea Exchange on March 24, Samchundang Pharmaceutical hit a new all-time high during the session, soaring to 1,025,000 won. The company achieved ‘king stock’ status during trading after six consecutive sessions of gains.


The company's share price, which was around 230,000 won at the end of last year, has jumped 322% since the start of this year. Despite domestic stock market instability due to geopolitical risks from the Middle East during the same period, the stock has risen about 19% this month alone, cementing its position as the new leader of the KOSDAQ market.


Anticipation for ‘Oral Obesity Medication’... Emerging as a Game Changer

The key driver behind the stock’s surge is anticipation for an ‘oral treatment.’ Samchundang Pharmaceutical is currently developing an oral formulation of a glucagon-like peptide-1 (GLP-1)-based obesity and diabetes treatment, an area where global pharmaceutical companies are fiercely competing. Since the current market is dominated by injectable drugs, the oral formulation, which offers greater convenience, is considered a potential ‘game changer’ that could reshape the market landscape.


Recently, progress in the development of oral insulin has also fueled investor sentiment. On March 19, Samchundang Pharmaceutical announced that it had submitted an IND (Investigational New Drug) application for a Phase 1/2 clinical trial in Europe. Following the news, the stock price soared 14% in a single day.


Samchundang Pharmaceutical, the leading stock of KOSDAQ, has continued to dominate on its own despite market volatility caused by adverse factors from the Middle East, finally reaching the status of a "king stock" (a share price of 1 million KRW). Photo by The Asia Business Daily Database

Samchundang Pharmaceutical, the leading stock of KOSDAQ, has continued to dominate on its own despite market volatility caused by adverse factors from the Middle East, finally reaching the status of a "king stock" (a share price of 1 million KRW). Photo by The Asia Business Daily Database

View original image

Industry sources anticipate that clinical results could be confirmed within this year. Experts have commented, "If the clinical trial is successful, it will bring the company close to developing the world’s first oral insulin," and added, "It has the potential to be a game changer in the market."


"The Stock Picked by Grandma"... Even Spreading as a Meme on Social Media

Alongside the stock’s meteoric rise, the so-called “Samchundang Grandma” story has also regained attention. In early February, a photo was posted on social media showing an elderly woman with white hair visiting a securities firm, handing a note to an employee. On the note, she had carefully written the names of the stocks and ETFs she intended to purchase, including ‘KODEX150 Leverage’ and ‘Samchundang Pharmaceutical.’


At that time, the share price was around 500,000 won—already double from the end of the previous year—which led some internet users to respond mockingly, saying, “If grandma is buying, it must be a signal that the price is peaking.”



However, after the share price doubled again to surpass 1 million won within a month, reactions have shifted. Now, comments such as “Grandma’s insight is better than the experts’” and “Grandma was the true master” are spreading, turning the story into a meme.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing